Faruqi and Faruqui, LLP Logo
Share this page

Derma Sciences, Inc. (DSCI)

(NasdaqCM: DSCI)


Faruqi & Faruqi, LLP Launches An Investigation Against Derma Sciences, Inc. (DSCI) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Derma Sciences, Inc. (“Derma” or the “Company”) (NasdaqCM: DSCI) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amendment to the Company’s 2012 Incentive Plan.

Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on April 12, 2013, the Board of Directors recommends that Derma’s shareholders vote to approve an amendment to the Derma Sciences, Inc. 2012 Equity Incentive Plan to increase the number of shares available for issuance thereunder in the amount of 1,687,500 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of Derma common stock.

If you own common stock in Derma and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Derma Sciences, Inc. (DSCI)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

MergerInfo Request
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.